Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan.
Biochem Pharmacol. 2020 May;175:113916. doi: 10.1016/j.bcp.2020.113916. Epub 2020 Mar 14.
The transport of UDP-glucuronic acid (UDPGA), a co-substrate of UDP-glucuronosyltransferase (UGT), to the intraluminal side of the endoplasmic reticulum (ER) is an essential step in the glucuronidation of exogenous and endogenous compounds. According to a previous study, the expression of recombinant SLC35B1, SLC35B4, or SLC35D1, nucleotide sugar transporters, in V79 cells has the potential to transport UDPGA into the lumen of microsomes. The purpose of this study is to examine whether the transport of UDPGA by these transporters substantially affects UGT activity. Since the knockdown of UDP-glucose 6-dehydrogenase, a synthetase of UDPGA, in HEK293 cells stably expressing UGT1A1 (HEK/UGT1A1 cells) resulted in a significant decrease in 4-methylumbelliferone (4-MU) glucuronosyltransferase activity, supplementation of a sufficient amount of UDPGA is required for UGT activity. By performing qRT-PCR using cDNA samples from 21 human liver samples, we observed levels of the SLC35B1 and SLC35D1 mRNAs that were 15- and 14-fold higher, respectively, than the levels of the SLC35B4 mRNA, and SLC35B1 showed the largest (37-fold) interindividual variability. Interestingly, 4-MU glucuronosyltransferase activity was significantly decreased upon the knockdown of SLC35B1 in HEK/UGT1A1 cells, and this phenomenon was also observed in HepaRG cells. Using siRNAs targeting 23 different SLC35 subfamilies, the knockdown of SLC35B1 and SLC35E3 decreased 4-MU glucuronosyltransferase activity in HEK/UGT1A1 cells. However, the 4-MU glucuronosyltransferase activity was not altered by SLC35E3 knockdown in HepaRG cells, suggesting that SLC35B1 was the main transporter of UDPGA into the ER in the human liver. In conclusion, SLC35B1 is a key modulator of UGT activity by transporting UDPGA to the intraluminal side of the ER.
UDP-葡萄糖醛酸(UDPGA)是 UDP-葡糖醛酸基转移酶(UGT)的共底物,将其转运到内质网(ER)的腔内侧是外源性和内源性化合物葡萄糖醛酸化的必要步骤。根据之前的一项研究,在 V79 细胞中表达重组核苷酸糖转运体 SLC35B1、SLC35B4 或 SLC35D1,有可能将 UDPGA 转运到微粒体的腔中。本研究旨在探讨这些转运体对 UDPGA 的转运是否会显著影响 UGT 活性。由于在稳定表达 UGT1A1 的 HEK293 细胞(HEK/UGT1A1 细胞)中敲低 UDP-葡萄糖 6-脱氢酶(UDPGA 的合成酶)会导致 4-甲基伞形酮(4-MU)葡萄糖醛酸基转移酶活性显著降低,因此需要补充足够量的 UDPGA 以维持 UGT 活性。通过使用来自 21 个人肝样本的 cDNA 样本进行 qRT-PCR,我们观察到 SLC35B1 和 SLC35D1 mRNA 的水平分别比 SLC35B4 mRNA 的水平高 15 倍和 14 倍,而 SLC35B1 表现出最大的(37 倍)个体间变异性。有趣的是,在 HEK/UGT1A1 细胞中敲低 SLC35B1 会显著降低 4-MU 葡萄糖醛酸基转移酶活性,在 HepaRG 细胞中也观察到了这种现象。使用针对 23 个不同 SLC35 亚家族的 siRNA,在 HEK/UGT1A1 细胞中敲低 SLC35B1 和 SLC35E3 会降低 4-MU 葡萄糖醛酸基转移酶活性。然而,在 HepaRG 细胞中敲低 SLC35E3 不会改变 4-MU 葡萄糖醛酸基转移酶活性,这表明 SLC35B1 是人类肝脏中 UDPGA 向 ER 腔内侧转运的主要转运体。总之,SLC35B1 通过将 UDPGA 转运到内质网的腔内侧,成为 UGT 活性的关键调节剂。